Literature DB >> 15616603

RNAi-mediated gene-targeting through systemic application of polyethylenimine (PEI)-complexed siRNA in vivo.

B Urban-Klein1, S Werth, S Abuharbeid, F Czubayko, A Aigner.   

Abstract

RNA interference (RNAi) represents a powerful, naturally occurring biological strategy for inhibition of gene expression. It is mediated through small interfering RNAs (siRNAs), which trigger specific mRNA degradation. In mammalian systems, however, the application of siRNAs is severely limited by the instability and poor delivery of unmodified siRNA molecules into the cells in vivo. In this study, we show that the noncovalent complexation of synthetic siRNAs with low molecular weight polyethylenimine (PEI) efficiently stabilizes siRNAs and delivers siRNAs into cells where they display full bioactivity at completely nontoxic concentrations. More importantly, in a subcutaneous mouse tumor model, the systemic (intraperitoneal, i.p.) administration of complexed, but not of naked siRNAs, leads to the delivery of the intact siRNAs into the tumors. The i.p. injection of PEI-complexed, but not of naked siRNAs targeting the c-erbB2/neu (HER-2) receptor results in a marked reduction of tumor growth through siRNA-mediated HER-2 downregulation. Hence, we establish a novel and simple system for the systemic in vivo application of siRNAs through PEI complexation as a powerful tool for future therapeutic use.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15616603     DOI: 10.1038/sj.gt.3302425

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  167 in total

1.  Duplex end breathing determines serum stability and intracellular potency of siRNA-Au NPs.

Authors:  Pinal C Patel; Liangliang Hao; Weng Si Au Yeung; Chad A Mirkin
Journal:  Mol Pharm       Date:  2011-06-28       Impact factor: 4.939

2.  Delivery of multiple siRNAs using lipid-coated PLGA nanoparticles for treatment of prostate cancer.

Authors:  Warefta Hasan; Kevin Chu; Anuradha Gullapalli; Stuart S Dunn; Elizabeth M Enlow; J Christopher Luft; Shaomin Tian; Mary E Napier; Patrick D Pohlhaus; Jason P Rolland; Joseph M DeSimone
Journal:  Nano Lett       Date:  2011-12-21       Impact factor: 11.189

3.  In vivo sustained release of siRNA from solid lipid nanoparticles.

Authors:  Tatsiana Lobovkina; Gunilla B Jacobson; Emilio Gonzalez-Gonzalez; Robyn P Hickerson; Devin Leake; Roger L Kaspar; Christopher H Contag; Richard N Zare
Journal:  ACS Nano       Date:  2011-11-18       Impact factor: 15.881

4.  Nanotechnology for energy-based cancer therapies.

Authors:  Kyle Gilstrap; Xiaoxiao Hu; Xiongbin Lu; Xiaoming He
Journal:  Am J Cancer Res       Date:  2011-03-11       Impact factor: 6.166

Review 5.  Delivery of siRNA therapeutics: barriers and carriers.

Authors:  Jie Wang; Ze Lu; M Guillaume Wientjes; Jessie L-S Au
Journal:  AAPS J       Date:  2010-06-11       Impact factor: 4.009

6.  Stem cell-based gene therapy activated using magnetic hyperthermia to enhance the treatment of cancer.

Authors:  Perry T Yin; Shreyas Shah; Nicholas J Pasquale; Olga B Garbuzenko; Tamara Minko; Ki-Bum Lee
Journal:  Biomaterials       Date:  2015-11-12       Impact factor: 12.479

7.  Targeting the blind spot of polycationic nanocarrier-based siRNA delivery.

Authors:  Mengyao Zheng; Giovanni M Pavan; Manuel Neeb; Andreas K Schaper; Andrea Danani; Gerhard Klebe; Olivia M Merkel; Thomas Kissel
Journal:  ACS Nano       Date:  2012-10-09       Impact factor: 15.881

8.  Potential advantages of DNA methyltransferase 1 (DNMT1)-targeted inhibition for cancer therapy.

Authors:  Yeonjoo Jung; Jinah Park; Tai Young Kim; Jung-Hyun Park; Hyun-Soon Jong; Seock-Ah Im; Keith D Robertson; Yung-Jue Bang; Tae-You Kim
Journal:  J Mol Med (Berl)       Date:  2007-06-15       Impact factor: 4.599

9.  Non-viral systemic delivery of Fas siRNA suppresses cyclophosphamide-induced diabetes in NOD mice.

Authors:  Ji Hoon Jeong; Sun Hwa Kim; Minhyung Lee; Won Jong Kim; Tae Gwan Park; Kyung Soo Ko; Sung Wan Kim
Journal:  J Control Release       Date:  2010-01-18       Impact factor: 9.776

10.  Degradable poly(ethylene glycol) (PEG)-based hydrogels for spatiotemporal control of siRNA/nanoparticle delivery.

Authors:  Yuchen Wang; Sue Zhang; Danielle S W Benoit
Journal:  J Control Release       Date:  2018-08-03       Impact factor: 9.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.